Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07683806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 44 → 52 locationsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
Trial Details
NCT Number NCT07683806
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Collaborators: Arcutis Biotherapeutics, Inc.
Conditions
(from sponsor)		 Seborrheic Dermatitis
Related terms Dermatitis, Seborrheic
Enrollment 309 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov